China Medical System & Mabgeek Biotechnology: A Strategic Partnership for Inflammatory Disease Treatment

China Medical System Holdings Limited (CMS) has entered into a strategic collaboration agreement with Hunan Mabgeek Biotechnology Co., Ltd. (Mabgeek Biotechnology) for the co-development and exclusive commercialization of MG-K10, a long-acting anti-IL-4Rα humanized monoclonal antibody injection. This partnership aligns with CMS's long-term strategy in the dermatology field and holds significant potential for addressing unmet needs in the market for type 2 inflammatory diseases.

MG-K10 is an innovative drug that simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 and IL-13, making it a promising treatment option for atopic dermatitis (AD), asthma, prurigo nodularis, and other inflammatory diseases. Its long-acting mechanism, achieved through Fc mutation, allows for a prolonged half-life and a dosing interval of every four weeks, compared to the currently marketed anti-IL-4Rα drugs that require dosing every two weeks. This extended dosing interval can improve patient adherence and convenience, potentially leading to better treatment outcomes and increased market share.

The global market for treatments targeting IL-4Rα is expected to reach US$28.7 billion by 2030, with a compound annual growth rate (CAGR) of 21.8% from 2020 to 2030. In China, the market is projected to reach US$4.08 billion by 2030, with a CAGR of 76.8% from 2020 to 2030. MG-K10's innovative design, long-acting mechanism, and favorable clinical trial results position it well to capture a significant share of this growing market.

In the completed Phase II clinical trials for adult moderate-to-severe AD and moderate-to-severe asthma, MG-K10 has demonstrated good efficacy and safety. Additionally, MG-K10 has obtained IND approval for eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis in China. These positive results indicate that MG-K10 has the potential to be an effective treatment option for patients with type 2 inflammatory diseases, further enhancing its competitive advantage in the market.

The collaboration between CMS and Mabgeek Biotechnology aligns with CMS's long-term strategy in the dermatology field by enriching its global differentiated innovative pipeline and synergizing with its existing product portfolio. MG-K10 will complement CMS's existing product portfolio, including marketed innovative drugs like ILUMETRI (tildrakizumab injection) and Hirudoid (mucopolysaccharide polysulfate cream), as well as dermatology-grade skincare products and pipeline drugs like ruxolitinib cream and povorcitinib. This synergy will allow CMS to offer a comprehensive range of treatments for type 2 inflammatory diseases, from topical creams to systemic injections.

In conclusion, the strategic partnership between China Medical System and Mabgeek Biotechnology for the co-development and exclusive commercialization of MG-K10 is well-positioned to address the growing market potential for treatments targeting IL-4Rα. With its innovative design, long-acting mechanism, and favorable clinical trial results, MG-K10 has the potential to become a leading treatment option for type 2 inflammatory diseases in China and beyond.